NCT04729257 is a NA clinical trial of Philips IntelliSpace Cognition (ISC). in Cognitive Functioning of Healthy Individuals, sponsored by Philips Electronics Nederland B.V. acting through Philips CTO organization.

What drugs are being tested in NCT04729257?

Interventions in NCT04729257: Philips IntelliSpace Cognition (ISC)., Paper-Pencil Tests..

What condition does NCT04729257 study?

NCT04729257 studies Cognitive Functioning of Healthy Individuals.

Is NCT04729257 still recruiting?

NCT04729257 is currently completed. Last updated 12 October 2021.

Last reviewed 2021-10-12 · How we verify

NCT04729257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Norms Expansion and Validation for IntelliSpace Cognition

Completed NA Last updated 12 October 2021

What this trial tests

NA trial testing Philips IntelliSpace Cognition (ISC). in Cognitive Functioning of Healthy Individuals in 508 participants. Completed in 2 July 2021.

Timeline

8 March 2021

Primary endpoint
2 July 2021

2 July 2021

Quick facts

Lead sponsor	Philips Electronics Nederland B.V. acting through Philips CTO organization
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	508
Start date	8 March 2021
Primary completion	2 July 2021
Estimated completion	2 July 2021
Sites	1 location across United States

Drugs / interventions tested

Philips IntelliSpace Cognition (ISC).
Paper-Pencil Tests.

Conditions studied

Cognitive Functioning of Healthy Individuals — all drugs for Cognitive Functioning of Healthy Individuals →

Sponsor

Philips Electronics Nederland B.V. acting through Philips CTO organization

Who can join

Adults 18 to 95, any sex, with Cognitive Functioning of Healthy Individuals. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical validity of IntelliSpace Cognition digital assessment platform in mild cognitive impairment.
Huijbers W, Pinter NK, Spaltman M, Cornelis M, et al · · 2024 · cited 1× · PMID 39807355 · DOI 10.3389/fpsyg.2024.1451843

Verify or expand the search:

Other Philips Electronics Nederland B.V. acting through Philips CTO organization trials

Trials by the same sponsor.

NCT05748184 — Fast Ultra Low Dose CT Interpretation · terminated
NCT05657665 — Skin Tone Measurement Method Investigation for Pulse Oximetry · completed
NCT05089955 — Children's MRI Experience · NA · completed
NCT05517096 — AmbuLatory Pediatric Asthma CAre · NA · withdrawn
NCT05540444 — RadConnect Communication Application · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04729257 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philips Electronics Nederland B.V. acting through Philips CTO organization
Last refreshed: 12 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04729257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing